242 related articles for article (PubMed ID: 1903340)
61. Antimicrobial agents--Part II. The aminoglycosides: streptomycin, kanamycin, gentamicin, tobramycin, amikacin, neomycin.
Brewer NS
Mayo Clin Proc; 1977 Nov; 52(11):675-9. PubMed ID: 336988
[TBL] [Abstract][Full Text] [Related]
62. [The effect of pharmacodynamic parameters of pefloxacin on elastase and protease activity in Pseudomonas aeruginosa].
Hostacká A
Epidemiol Mikrobiol Imunol; 1996 Sep; 45(3):119-22. PubMed ID: 8998604
[TBL] [Abstract][Full Text] [Related]
63. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa.
Alipour M; Suntres ZE; Omri A
J Antimicrob Chemother; 2009 Aug; 64(2):317-25. PubMed ID: 19465435
[TBL] [Abstract][Full Text] [Related]
64. Frequencies of variants resistant to different aminoglycosides in Pseudomonas aeruginosa.
Nilsson L; Sörén L; Rådberg G
J Antimicrob Chemother; 1987 Aug; 20(2):255-9. PubMed ID: 3117761
[TBL] [Abstract][Full Text] [Related]
65. Comparison of two techniques for measurement of in vitro killing kinetics of five antibiotics against Pseudomonas aeruginosa.
Lesage D; Delisle F; Richard G; Burghoffer B; Le Cunff D; Petit JC
Eur J Clin Microbiol Infect Dis; 1994 May; 13(5):412-7. PubMed ID: 8070456
[TBL] [Abstract][Full Text] [Related]
66. Comparative evaluation of the micro-media system, sceptor, and MIC-2000 microdilution methods for testing Pseudomonas aeruginosa against gentamicin, tobramycin, and amikacin.
Woolfrey BF; Lally RT; Quall CO
J Clin Microbiol; 1983 Feb; 17(2):312-6. PubMed ID: 6403574
[TBL] [Abstract][Full Text] [Related]
67. [Comparison of the antibacterial activity of amikacin (BB-K8) with other aminoglycosides against pathogens recently isolated from clinical materials (author's transl) ].
Kosakai N; Oguri T
Jpn J Antibiot; 1975 Aug; 28(4):530-7. PubMed ID: 240047
[TBL] [Abstract][Full Text] [Related]
68. Pharmacodynamics of beta-lactam antibiotics. Studies on the paradoxical and postantibiotic effects in vitro and in an animal model.
Odenholt-Tornqvist I
Scand J Infect Dis Suppl; 1989; 58():1-55. PubMed ID: 2499924
[TBL] [Abstract][Full Text] [Related]
69. L-658,310, a new injectable cephalosporin. II. In vitro and in vivo interactions between L-658,310 and various aminoglycosides or ciprofloxacin versus clinical isolates of Pseudomonas aeruginosa.
Valiant ME; Gilfillan EC; Gadebusch HH; Pelak BA
J Antibiot (Tokyo); 1989 May; 42(5):807-14. PubMed ID: 2498278
[TBL] [Abstract][Full Text] [Related]
70. Outer membrane proteins and elastase of Pseudomonas aeruginosa after the postantibiotic effect induced by amikacin.
Hostacká A; Karelová E
Chemotherapy; 1997; 43(2):118-22. PubMed ID: 9084920
[TBL] [Abstract][Full Text] [Related]
71. Comparison of methodologies for synergism testing of drug combinations against resistant strains of Pseudomonas aeruginosa.
Cappelletty DM; Rybak MJ
Antimicrob Agents Chemother; 1996 Mar; 40(3):677-83. PubMed ID: 8851592
[TBL] [Abstract][Full Text] [Related]
72. The Lon protease of Pseudomonas aeruginosa is induced by aminoglycosides and is involved in biofilm formation and motility.
Marr AK; Overhage J; Bains M; Hancock REW
Microbiology (Reading); 2007 Feb; 153(Pt 2):474-482. PubMed ID: 17259618
[TBL] [Abstract][Full Text] [Related]
73. Hydrophobicity and outer membrane proteins of Shigella dysenteriae type 1 after treatment with subinhibitory concentrations of aminoglycosides.
Hostacká A; Karelová E
Folia Microbiol (Praha); 1997; 42(6):565-8. PubMed ID: 9438357
[TBL] [Abstract][Full Text] [Related]
74. Changes in MIC alter responses of Pseudomonas aeruginosa to tobramycin exposure.
Ioannides-Demos LL; Liolios L; Wood P; Spicer WJ; McLean AJ
Antimicrob Agents Chemother; 1998 Jun; 42(6):1365-9. PubMed ID: 9624477
[TBL] [Abstract][Full Text] [Related]
75. Evaluation of the automicrobic system for susceptibility testing of Pseudomonas aeruginosa to gentamicin, tobramycin, and amikacin.
Woolfrey BF; Lally RT; Ederer MN; Quall CO
J Clin Microbiol; 1984 Apr; 19(4):502-5. PubMed ID: 6425360
[TBL] [Abstract][Full Text] [Related]
76. Performance of a commercial microdilution minimal inhibitory concentration procedure for aminoglycoside susceptibility testing of Pseudomonas aeruginosa.
Etowski DC; Beckwith DG
Am J Clin Pathol; 1981 Jun; 75(6):830-3. PubMed ID: 6789668
[TBL] [Abstract][Full Text] [Related]
77. Postantibiotic effect of imipenem, alone and in combination with amikacin, on Pseudomonas aeruginosa.
Gerçeker AA; Otük G
Chemotherapy; 1995; 41(6):433-6. PubMed ID: 8529433
[TBL] [Abstract][Full Text] [Related]
78. In vitro characterization of aminoglycoside adaptive resistance in Pseudomonas aeruginosa.
Karlowsky JA; Saunders MH; Harding GA; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 1996 Jun; 40(6):1387-93. PubMed ID: 8726006
[TBL] [Abstract][Full Text] [Related]
79. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin.
Odenholt-Tornqvist I; Löwdin E; Cars O
Antimicrob Agents Chemother; 1992 Sep; 36(9):1852-8. PubMed ID: 1329631
[TBL] [Abstract][Full Text] [Related]
80. Alteration of postantibiotic effect during one dosing interval of tobramycin, simulated in an in vitro pharmacokinetic model.
den Hollander JG; Mouton JW; van Goor MP; Vleggaar FP; Verbrugh HA
Antimicrob Agents Chemother; 1996 Mar; 40(3):784-6. PubMed ID: 8851612
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
